Jefferies Group's DNLI Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 34,425 shares of Denali Therapeutics Inc. (DNLI) worth $660,960, representing 0.00% of the portfolio. First purchased in 2023-Q1, this short-term holding has been held for 7 quarters.
Based on 13F filings, Jefferies Group has maintained this position in DNLI for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2023, adding 152,527 shares. Largest reduction occurred in Q2 2023, reducing 263,123 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Denali Therapeutics (DNLI) Holding Value Over Time
Track share changes against reported price movement
Quarterly Denali Therapeutics (DNLI) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +34,425 | New Buy | 34,425 | $19.20 |
| Q2 2024 | -69,314 | Sold Out | 0 | $0.00 |
| Q1 2024 | -96,013 | Reduce 58.07% | 69,314 | $20.52 |
| Q4 2023 | +152,527 | Add 1191.62% | 165,327 | $21.46 |
| Q3 2023 | +12,800 | New Buy | 12,800 | $20.63 |
| Q2 2023 | -263,123 | Sold Out | 0 | $0.00 |
| Q1 2023 | +263,123 | New Buy | 263,123 | $23.04 |
Jefferies Group's Denali Therapeutics Investment FAQs
Jefferies Group first purchased Denali Therapeutics Inc. (DNLI) in Q1 2023, acquiring 263,123 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Denali Therapeutics Inc. (DNLI) for 7 quarters since Q1 2023.
Jefferies Group's largest addition to Denali Therapeutics Inc. (DNLI) was in Q1 2023, adding 263,123 shares worth $6.06 M.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 34,425 shares of Denali Therapeutics Inc. (DNLI), valued at approximately $660,960.
As of the Q1 2026 filing, Denali Therapeutics Inc. (DNLI) represents approximately 0.00% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Denali Therapeutics Inc. (DNLI) was 263,123 shares, as reported at the end of Q1 2023.